Clinical Trial Update: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

View source ↗

Summary

A clinical trial evaluating guselekumab for shared pathways in psoriasis, psoriatic arthritis, and nonalcoholic fatty liver disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Guselekumab (guselekumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Psoriasis (PsO), PsA (Psoriatic Arthritis) | Status: WITHDRAWN